Liatsou I - Search Results

1

Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma.

Fu Y, Yu J, Liatsou I, Du Y, Josefsson A, Nedrow JR, Rindt H, Bryan JN, Kraitchman DL, Sgouros G. Fu Y, et al. Among authors: liatsou i. Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4382-4393. doi: 10.1007/s00259-022-05888-5. Epub 2022 Jul 9. Eur J Nucl Med Mol Imaging. 2022. PMID: 35809088

2

²¹²Pb-conjugated anti-rat HER2/neu antibody against a neu-N derived murine mammary carcinoma cell line: cell kill and RBE in vitro.

Liatsou I, Yu J, Bastiaannet R, Li Z, Hobbs RF, Torgue J, Sgouros G. Liatsou I, et al. Int J Radiat Biol. 2022;98(9):1452-1461. doi: 10.1080/09553002.2022.2033341. Epub 2022 Feb 9. Int J Radiat Biol. 2022. PMID: 35073214 Free PMC article.

3

Bone Marrow Relative Biological Effectiveness for a ²¹²Pb-labeled Anti-HER2/neu Antibody.

Liatsou I, Josefsson A, Yu J, Cortez A, Bastiaannet R, Velarde E, Davis K, Brayton C, Wang H, Torgue J, Hobbs RF, Sgouros G. Liatsou I, et al. Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):518-528. doi: 10.1016/j.ijrobp.2022.07.1842. Epub 2022 Aug 1. Int J Radiat Oncol Biol Phys. 2023. PMID: 35926719

4

Large-scale in vitro microdosimetry via live cell microscopy imaging: implications for radiosensitivity and RBE evaluations in alpha-emitter radiopharmaceutical therapy.

Bastiaannet R, Liatsou I, F Hobbs R, Sgouros G. Bastiaannet R, et al. Among authors: liatsou i. J Transl Med. 2023 Feb 24;21(1):144. doi: 10.1186/s12967-023-03991-1. J Transl Med. 2023. PMID: 36829143 Free PMC article.

5

Early Normal Tissue Effects and Bone Marrow Relative Biological Effectiveness for an Actinium 225-Labeled HER2/neu-Targeting Antibody.

Liatsou I, Josefsson A, Yu J, Li Z, Davis K, Brayton C, Wang H, Hobbs RF, Sgouros G. Liatsou I, et al. Int J Radiat Oncol Biol Phys. 2023 Nov 15;117(4):1028-1037. doi: 10.1016/j.ijrobp.2023.06.003. Epub 2023 Jun 17. Int J Radiat Oncol Biol Phys. 2023. PMID: 37331568

6

Development and therapeutic evaluation of 5D3(CC-MLN8237)_3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy.

Liatsou I, Assefa B, Liyanage W, Surasinghe S, Nováková Z, Bařinka C, Gabrielson K, Raman V, Artemov D, Hapuarachchige S. Liatsou I, et al. Front Pharmacol. 2024 May 1;15:1385598. doi: 10.3389/fphar.2024.1385598. eCollection 2024. Front Pharmacol. 2024. PMID: 38751786 Free PMC article.

7

Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma-a proof of concept study.

Liatsou I, Fu Y, Li Z, Hasan M, Guo X, Yu J, Piccolo J, Cartee A, Wang H, Du Y, Bryan J, Gabrielson K, Kraitchman DL, Sgouros G. Liatsou I, et al. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1409-1420. doi: 10.1007/s00259-023-06528-2. Epub 2023 Dec 18. Eur J Nucl Med Mol Imaging. 2024. PMID: 38108831

8

Gel-forming therapeutic peptide exhibits sustained delivery and efficacy in a mouse model of triple-negative breast cancer.

Patil A, Mirando AC, Liatsou I, Sgouros G, Popel AS, Pandey NB. Patil A, et al. Among authors: liatsou i. Peptides. 2023 Nov;169:171075. doi: 10.1016/j.peptides.2023.171075. Epub 2023 Aug 15. Peptides. 2023. PMID: 37591441 Free PMC article.

9

Cu(II) adsorption on 2-thiouracil-modified Luffa cylindrica biochar fibres from artificial and real samples, and competition reactions with U(VI).

Liatsou I, Pashalidis I, Dosche C. Liatsou I, et al. J Hazard Mater. 2020 Feb 5;383:120950. doi: 10.1016/j.jhazmat.2019.120950. Epub 2019 Aug 3. J Hazard Mater. 2020. PMID: 31541960

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters